UC BON.CAP.CERT. 06/25 SNW/ DE000HD5NWJ4 /
27/12/2024 21:46:36 | Diferencia+3.590 | Bid21:59:33 | Ask21:59:33 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
122.190EUR | +3.03% | 121.580 Volumen de oferta: 500 |
122.680 Tamaño/ Volumen/ Formato de Ask: 500 |
SANOFI SA INHABER ... | - - | 27/06/2025 | Call |
GlobeNewswire
02/09
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
26/08
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
14/08
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
13/08
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
12/08
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08/08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
06/08
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
01/08
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
31/07
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
25/07
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
25/07
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
24/07
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página